-
Corder Rare Disease Center and Story FM launches "Rare Cafe" Story Salon
Time of Update: 2021-07-23
Tang Fenglei, representative of patients with Fabry disease "Since the age of eighteen, my hands, feet, face, and body have had edema without warning, and my abdomen often suffers from unexplained pain.
-
Weijian Pharmaceutical and German Marksman once again signed a contract with Yabos to benefit domestic patients with hepatic encephalopathy
Time of Update: 2021-07-23
On February 26, 2021, Hong Kong Weijian Pharmaceutical Group and the German Max Pharmaceutical Factory announced a strategic cooperation .
The strategic cooperation between the two sides, marking the Victoria Health Medical German Maxwell's significant products Ya Division ® (ornithine aspartate) commercial interests in China .
-
Hebo Medicine's new generation of anti-CTLA-4 antibody HBM4003 has made new progress
Time of Update: 2021-07-23
Hebo Pharmaceutical announced today that the National Medical Products Administration (NMPA) approved its research product anti-CTLA-4 fully human monoclonal heavy chain antibody HBM4003 and PD-1 antibody/chemotherapy for the treatment of advanced non-small cell lung cancer and other solid tumors Patient's clinical trial application .
-
Li Dongjiu, director of Sinopharm Accord, resigns
Time of Update: 2021-07-22
Li Dongjiu applied for resignation from the positions of director of the eighth board of directors, strategic committee of the board of directors, and member of the legal compliance committee of the board of directors due to the adjustment of work arrangements .
-
Jincheng Medicine Ceftriaxone Sodium for Injection Passed the Quality and Efficacy Consistency Evaluation of Generic Drugs
Time of Update: 2021-07-22
On March 2, Jincheng Pharmaceutical announced that its subsidiary Ceftriaxone Sodium for Injection passed the generic drug quality and efficacy consistency evaluation .
Ceftriaxone Sodium for Injection by Jincheng Medicine was first approved by the former State Food and Drug Administration on April 30, 2004.
-
Yilian Biotechnology completes 350 million yuan A round of financing, ADC track continues to be hot
Time of Update: 2021-07-22
He has rich experience in the research and development, commercialization of biological drugs and small molecule products, as well as domestic and foreign business cooperation; CSO Dr.
-
Zhao Wanshun, deputy general manager of Xinlitai, resigns
Time of Update: 2021-07-22
Zhao Wanshun applied to resign from the position of deputy general manager of the company due to personal reasons .
According to the "Guidelines for the Normative Operation of Listed Companies on the Shenzhen Stock Exchange" and the "Articles of Association", Zhao Wanshun's resignation report will take effect when it is delivered to the board of directors .
-
Children with hearing loss cannot be ignored Cochlear calls for early and correct intervention
Time of Update: 2021-07-21
Do a good job in hearing and speech rehabilitation, so that children can integrate into mainstream schools "Early intervention" helps children with hearing loss to gain "hearing", but this is only the starting point of the listening journey.
-
National People's Congress Representative Yu Qingming: Sinopharm's annual production capacity of new crown vaccine will reach 3 billion doses
Time of Update: 2021-07-21
Yu Qingming: The results of large-scale overseas clinical trial data approved by governments of various countries show that Sinopharm's new crown vaccine has a protective effect of 86%, a neutralizing antibody conversion rate of more than 99%, an effective prevention of moderate cases, and an effective prevention of severe cases.
-
Sunward Medical terminates the IPO of Science and Technology Innovation Board
Time of Update: 2021-07-21
According to information from the Shanghai Stock Exchange, the termination of the Sunwo Medical Sci-tech Innovation Board IPO was due to the withdrawal of the application documents by the sponsor .
-
Novartis disbands oxcarbazepine sales team
Time of Update: 2021-07-21
Recently, news broke that the sales team for oxcarbazepine tablets of Novartis’s CNS product line has been disbanded .
It is reported that Novartis' oxcarbazepine tablets have not been purchased in quantity, and there is no news that Novartis will transfer the product line .
-
WuXi AppTec announces the completion of the acquisition of OXGENE and continues to strengthen its global service capabilities for cell and gene therapy
Time of Update: 2021-07-21
“We are very happy to join WuXiGene and work together Strengthen the large-scale application of innovative technologies, continue to expand service capabilities, and help customers significantly increase production capacity and reduce costs, so that more cell and gene therapies can come out as soon as possible, and benefit patients worldwide .
-
Cipla obtains final approval for the generic version of GlaxoSmithKline
Time of Update: 2021-07-21
S. Pharmacopoeia 20 mg sumatriptan nasal spray is a generic version of the Class AB generic treatment of GlaxoSmithKline Imtrex® nasal spray .
Imitrex® nasal spray is a serotonin (5-HT1B/1D) receptor agonist (triptan), suitable for the acute treatment of adult migraine with or without aura .
-
Saisheng Pharmaceutical is listed on the main board of the Hong Kong Stock Exchange
Time of Update: 2021-07-21
Saisheng Pharmaceuticals will continue to screen for investment opportunities in candidate drugs for tumors and severe infections, in order to form a synergistic strengthening effect with the advantages of existing pipelines and commercialization capabilities .
-
Takeda acquires epilepsy drug soticlestat for $856 million
Time of Update: 2021-07-21
Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome
-
Junshi Bio: JS103 injection received the notification of acceptance of drug clinical trial application
Time of Update: 2021-07-21
JS103 is a pegylated uricase derivative independently developed by the company, which is mainly used for the treatment of hyperuricemia with or without gout .
JS103 is a pegylated uricase derivative independently developed by the company.
-
Changchun High-tech nasal spray influenza live attenuated vaccine (liquid dosage form) was approved for clinical trials
Time of Update: 2021-07-21
After review by the State Food and Drug Administration, the live attenuated nasal spray influenza vaccine accepted on December 2, 2020 meets the relevant requirements of drug registration, and agreed to carry out clinical trials to prevent influenza caused by this strain of the virus in accordance with the submitted plan .
-
2020 Top 15 Medical Technology Companies
Time of Update: 2021-07-20
Ellume CEO: Sean Parsons Established time: 2010 Headquarters: Brisbane The Australian company Ellume has developed the first COVID-19 test that can be sold over the counter in the United States without a doctor's prescription .
-
The global medical industry fund jointly created by AstraZeneca and CICC Capital completed the first round of fundraising
Time of Update: 2021-07-20
Today, AstraZeneca and CICC Capital formally announced that the first global medical industry fund "AstraZeneca CICC Medical Venture Capital" jointly created by the two parties has completed Phase I financing and will be listed in China Securities on January 28, 2021.
-
Fortune Huaning Biopharmaceuticals and China Merchants Group's health sector strategic cooperation and C round financing signing
Time of Update: 2021-07-20
At the same time, the health sector of China Merchants Group and Fortune Huaning Bio-Pharmaceuticals will also jointly integrate resources in the promotion of new drug research and development, digital production base building, and product market expansion, and launch full-chain cooperation to help Fortune Huaning Bio-Pharmaceuticals complete several important tasks as soon as possible.
